GSA Capital Partners LLP Buys Shares of 118,593 Tango Therapeutics, Inc. $TNGX

GSA Capital Partners LLP bought a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 118,593 shares of the company’s stock, valued at approximately $1,051,000.

Several other hedge funds have also recently added to or reduced their stakes in TNGX. Tudor Investment Corp ET AL bought a new stake in shares of Tango Therapeutics in the 3rd quarter worth $450,000. Farallon Capital Management LLC raised its stake in shares of Tango Therapeutics by 17.5% in the 3rd quarter. Farallon Capital Management LLC now owns 10,757,000 shares of the company’s stock worth $90,359,000 after buying an additional 1,600,000 shares in the last quarter. Mass General Brigham Inc bought a new stake in shares of Tango Therapeutics in the 4th quarter worth $3,138,000. Rafferty Asset Management LLC bought a new stake in shares of Tango Therapeutics in the 3rd quarter worth $1,221,000. Finally, Avoro Capital Advisors LLC bought a new stake in shares of Tango Therapeutics in the 3rd quarter worth $4,578,000. Institutional investors own 78.99% of the company’s stock.

Insider Buying and Selling at Tango Therapeutics

In other news, insider Adam Crystal sold 54,345 shares of Tango Therapeutics stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $12.77, for a total transaction of $693,985.65. Following the transaction, the insider owned 132,873 shares in the company, valued at approximately $1,696,788.21. The trade was a 29.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 179,056 shares of company stock worth $3,346,181 in the last quarter. Insiders own 6.50% of the company’s stock.

Tango Therapeutics Stock Up 2.6%

Shares of Tango Therapeutics stock opened at $21.62 on Friday. The stock’s fifty day moving average is $21.91 and its 200-day moving average is $14.65. The firm has a market capitalization of $3.13 billion, a PE ratio of -26.05 and a beta of 1.22. Tango Therapeutics, Inc. has a 12-month low of $1.72 and a 12-month high of $28.41.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.32). Tango Therapeutics had a negative return on equity of 41.54% and a negative net margin of 151.15%. Analysts expect that Tango Therapeutics, Inc. will post -1.34 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Stifel Nicolaus boosted their price objective on Tango Therapeutics from $24.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. Guggenheim boosted their price objective on Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Mizuho boosted their price objective on Tango Therapeutics from $20.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th. HC Wainwright boosted their price objective on Tango Therapeutics from $13.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Finally, Wedbush boosted their price objective on Tango Therapeutics from $19.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Tango Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $32.27.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.